| 翻訳と辞書 |
| Albinterferon ： ウィキペディア英語版 |
Albinterferon
Albinterferon (alb-IFN, trade name Albuferon) is a recombinant fusion protein drug consisting of interferon alpha (IFN-α) linked to human albumin.〔(Statement on a nonproprietary name adopted by the USAN Council )〕 Conjugation to human albumin prolongs the half-life of the IFN-α to about 6 days, allowing to dose it every two to four weeks.
The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they will cease development of the drug.〔http://www.google.com/hostednews/ap/article/ALeqM5h_xwTjacvhKutLYGE0w6FEuuaEQwD9ILM7MG1?docId=D9ILM7MG1〕
A French expert in hepatitis treatment, Dr. Yves Benhamou, member of the steering committee for a clinical trial of the drug was detained on criminal fraud charges by the F.B.I. agents on 11-01-2010 as he attended a conference in Boston because he allegedly tipped off a hedge fund manager about setbacks in the clinical trials (two participants in the trial had developed lung disease and one of them died); he had a consulting relationship with a manager of the hedge fund. The manager sold his entire stake in Human Genome Sciences before it announced the setbacks in Jan. 2008 and avoided $30 million in losses.〔http://newyork.fbi.gov/dojpressrel/pressrel10/nyfo110210a.htm〕
==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Albinterferon」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|